GlassScriptPhysician profile
Ravi Patel
NPI 1134133358
$55,135.24
in general payments reported to CMS, 2019-2025
31 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $9,399 · 2021: $4,590 · 2022: $2,560 · 2023: $6,546 · 2024: $8,118 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Food and Beverage: $4,803 · Travel and Lodging: $1,018 · Honoraria: $96.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,833.92 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Food and Beverage | $4,802.53 |
| Travel and Lodging | $1,017.83 |
| Honoraria | $96.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $23,672.20 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $12,374.85 | 2019-2025 | Kxl System, Ce-Marked Kxla System, Photrexa Viscous and Photrexa |
| Johnson & Johnson Surgical Vision, INC. | $10,957.32 | 2019-2025 | Tecnis Iol, Catalys System, Tecnis Simplicity |
| Omeros Corporation | $3,116.48 | 2019 | |
| Alcon Vision LLC | $1,610.13 | 2019-2025 | Clareon, Luxor, Hydrus Microstent |
| Rxsight INC | $503.60 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $488.35 | 2022-2025 | Envista Mx60 Iol, Vyzulta, Envista Envy Iol |
| Horizon Therapeutics Plc | $284.37 | 2022-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $266.00 | 2019-2021 | |
| Harrow Eye, LLC | $252.61 | 2024-2025 | Iheezo, Vevye |
| Sun Pharmaceutical Industries INC. | $227.03 | 2019-2025 | |
| Allergan, INC. | $226.22 | 2021 | |
| Oyster Point Pharma, INC. | $212.51 | 2022-2023 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $168.27 | 2019-2020 | |
| Astellas Pharma US INC | $126.85 | 2025 | Izervay |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $126.15 | 2019-2022 | |
| Biotissue Holdings INC. | $103.71 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $76.79 | 2022-2025 | Acthar |
| Abbvie INC. | $57.40 | 2023-2024 | |
| Amgen INC. | $55.49 | 2024 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $33.98 | 2023-2025 | |
| Dompe US, INC. | $33.34 | 2021-2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $23.34 | 2020 | |
| Dendreon Pharmaceuticals LLC | $20.47 | 2025 | Provenge |
| Ivantis, INC | $19.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.44 | 2019 | |
| Rayner Intraocular Lenses Limited | $19.09 | 2022 | |
| Heron Therapeutics, INC. | $17.19 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.00 | 2024 | |
| Emmaus Medical, INC. | $16.20 | 2021 | |
| Lensar, INC. | $9.38 | 2024 | Lensar Laser System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.